189 related articles for article (PubMed ID: 19663918)
1. Intensive insulin therapy decreases urinary MCP-1 and ICAM-1 excretions in incipient diabetic nephropathy.
Ye SD; Zheng M; Zhao LL; Qian Y; Yao XM; Ren A; Li SM; Jing CY
Eur J Clin Invest; 2009 Nov; 39(11):980-5. PubMed ID: 19663918
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in type 2 diabetes mellitus.
Wang QY; Chen FQ
Diabetes Res Clin Pract; 2009 Feb; 83(2):215-9. PubMed ID: 19097668
[TBL] [Abstract][Full Text] [Related]
3. Intercellular adhesion molecule, plasma adiponectin and albuminuria in type 2 diabetic patients.
Lenghel AR; Kacso IM; Bondor CI; Rusu C; Rahaian R; Gherman Caprioara M
Diabetes Res Clin Pract; 2012 Jan; 95(1):55-61. PubMed ID: 21945031
[TBL] [Abstract][Full Text] [Related]
4. Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients.
Takebayashi K; Matsumoto S; Aso Y; Inukai T
J Diabetes Complications; 2006; 20(2):98-104. PubMed ID: 16504838
[TBL] [Abstract][Full Text] [Related]
5. Effects of long-term pravastatin treatment on serum and urinary monocyte chemoattractant protein-1 levels and renal function in type 2 diabetic patients with normoalbuminuria.
Fujita H; Koshimura J; Sato T; Miura T; Sasaki H; Morii T; Narita T; Kakei M; Ito S; Yamada Y
Ren Fail; 2007; 29(7):791-6. PubMed ID: 17994445
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression.
Zheng M; Ye S; Zhai Z; Chen Y; Li X; Yang G; Fan A; Wang Y
J Diabetes Complications; 2009; 23(2):124-9. PubMed ID: 18413206
[TBL] [Abstract][Full Text] [Related]
7. Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients.
Wirta OR; Pasternack AI; Mustonen JT; Koivula TA; Harmoinen A
Nephrol Dial Transplant; 1996 Mar; 11(3):449-56. PubMed ID: 8671814
[TBL] [Abstract][Full Text] [Related]
8. Relationships among microalbuminuria, insulin resistance and renal-cardiac complications in insulin dependent and non insulin dependent diabetes.
Nosadini R; Brocco E
Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():1-7. PubMed ID: 9288531
[TBL] [Abstract][Full Text] [Related]
9. Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy.
Titan SM; Vieira JM; Dominguez WV; Moreira SR; Pereira AB; Barros RT; Zatz R
J Diabetes Complications; 2012; 26(6):546-53. PubMed ID: 22981148
[TBL] [Abstract][Full Text] [Related]
10. Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy.
Ha SW; Kim HJ; Bae JS; Jeong GH; Chung SC; Kim JG; Park SH; Kim YL; Kam S; Kim IS; Kim BW
Diabetes Res Clin Pract; 2004 Aug; 65(2):167-73. PubMed ID: 15223229
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.
Shichiri M; Kishikawa H; Ohkubo Y; Wake N
Diabetes Care; 2000 Apr; 23 Suppl 2():B21-9. PubMed ID: 10860187
[TBL] [Abstract][Full Text] [Related]
12. Albuminuria induced by exercise in hypertensive type I and type II diabetic patients: a randomised, double-blind study on the effects of acute administration of captopril and nifedipine.
Romanelli G; Giustina A; Cravarezza P; Caldonazzo A; Agabiti-Rosei E; Giustina G
J Hum Hypertens; 1991 Jun; 5(3):167-73. PubMed ID: 1920340
[TBL] [Abstract][Full Text] [Related]
13. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
14. Colchicine attenuates inflammatory cell infiltration and extracellular matrix accumulation in diabetic nephropathy.
Li JJ; Lee SH; Kim DK; Jin R; Jung DS; Kwak SJ; Kim SH; Han SH; Lee JE; Moon SJ; Ryu DR; Yoo TH; Han DS; Kang SW
Am J Physiol Renal Physiol; 2009 Jul; 297(1):F200-9. PubMed ID: 19369290
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor beta 1 and monocyte chemoattractant protein-1 as prognostic markers of diabetic nephropathy.
Shaker OG; Sadik NA
Hum Exp Toxicol; 2013 Oct; 32(10):1089-96. PubMed ID: 23515495
[TBL] [Abstract][Full Text] [Related]
16. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy.
Banba N; Nakamura T; Matsumura M; Kuroda H; Hattori Y; Kasai K
Kidney Int; 2000 Aug; 58(2):684-90. PubMed ID: 10916091
[TBL] [Abstract][Full Text] [Related]
17. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design.
Shikata K; Haneda M; Koya D; Suzuki Y; Tomino Y; Yamada K; Maeda S; Kawakami N; Uzu T; Nishimura M; Sato C; Ogawa D; Makino H;
Diabetes Res Clin Pract; 2010 Feb; 87(2):228-32. PubMed ID: 19889469
[TBL] [Abstract][Full Text] [Related]
18. Increased urinary excretion of monocyte chemoattractant protein-1 during acute renal allograft rejection.
Prodjosudjadi W; Daha MR; Gerritsma JS; Florijn KW; Barendregt JN; Bruijn JA; van der Woude FJ; van Es LA
Nephrol Dial Transplant; 1996 Jun; 11(6):1096-103. PubMed ID: 8671975
[TBL] [Abstract][Full Text] [Related]
19. Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes.
Chuahirun T; Khanna A; Kimball K; Wesson DE
Am J Kidney Dis; 2003 Jan; 41(1):13-21. PubMed ID: 12500217
[TBL] [Abstract][Full Text] [Related]
20. Familial factors in diabetic nephropathy: an offspring study.
Agius E; Attard G; Shakespeare L; Clark P; Vidya MA; Hattersley AT; Fava S
Diabet Med; 2006 Mar; 23(3):331-4. PubMed ID: 16492220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
